The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 123 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] Ness-Abramof, 2002, Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese., Obes Res sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] Smith, 1996, Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues., J Clin Endocrinol Metab source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] Pecori Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series., J Clin Endocrinol Metab source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] Batista, 2007, Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
“Increased late night salivary cortisol Dexamethasone suppression tests [118]”
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationFassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Self-citation2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
“(17) 2810 Nieman et al Guidelines on Cushing’s Syndrome Treatment J Clin Endocrinol Metab, August 2015, 100(8):2807–2831”
BackgroundSelf-citationCarey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127
Diagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.06.010 · Cited by 947
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
“5,27 One advantage with UFC over DST is that overall cortisol production is independent of CBG changes and dexamethasone metabolism or compliance.”
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.005 · Cited by 920
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000597 · Cited by 902
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
“agnosing subclinical Cushing’s syndrome (93).”
BackgroundFassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
“For 61-63 Due to the fact that some of the above-mentioned entities require specific management, it is usually required to get advice from an experienced center with an adrenal multidisciplinary expert team meeting (see R.1.1).”
BackgroundInfluentialSelf-citationComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline
Gordon, C. M., Ackerman, K. E., Berga, S. L., Kaplan, J. R., Mastorakos, G., Misra, M., Murad, M. H., Santoro, N. F., & Warren, M. P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00131 · Cited by 600
Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
Freda, P. U., Beckers, A. M., Katznelson, L., Molitch, M. E., Montori, V. M., Post, K. D., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1048 · Cited by 585
“• Hypersecreting tumors other than prolactinomas as recommended by other guidelines of The Endocrine Society and The Pituitary Society.”
BackgroundInfluentialSelf-citationThe Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
“The reduced amplitude of the circadian cortisol rhythm associated with higher nadir levels is, in clinical practice, an early marker of hypercortisolism in humans, and the evaluation of cortisol levels during the normal nadir of the rhythm is a common screening test to diagnose Cushing’s syndrome (357).”
AME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V, Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 520
“According to the Endocrine Society‟s Clinical Guidelines for the diagnosis of Cushing‟s syndrome and the AACE/AAES Medical Guidelines for the Management of Adrenal Incidentalomas, all patients with an incidentally discovered adrenal mass should be tested for hypercortisolism (89).”
InfluentialZeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
“The 1-mg dexamethasone suppres - sion test is more sensitive than UFC in diagnosing this condition (29 [EL 4]) .”
InfluentialFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Dynamics of ACTH and Cortisol Secretion and Implications for Disease
Lightman, S. L., Birnie, M. T., & Conway-Campbell, B. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa002 · Cited by 439
“Along with myriad metabolic adverse effects and cardiovascular risks (147), patients with CS demonstrate deficits in memory, and a wide range of cognitive impairments and mood disorders (148,149) as well as predisposition to anxiety and depression (150).”
BackgroundValassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402
Measuring cortisol in serum, urine and saliva—Are our assays good enough?
El-Farhan, N., Rees, D. A., & Evans, C. (2017) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216687335 · Cited by 395
“In 2008, the American Endocrine Society’s Clinical Guidelines Subcommittee published a guideline on the diagnosis of Cushing’s syndrome.(99) The authors collated evidence from studies that had demonstrated significant treatment benefit in patients diagnosed with Cushing’s syndrome to identify the tests that best detec…”
BackgroundMethodInfluentialMortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Self-citationSecondary arterial hypertension: when, who, and how to screen?
Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht534 · Cited by 393
“Patients with this syndrome display a typical body habitus with obesity, facial plethora, buffalo hump, hirsutism, and purple striae.(75) Hypertension is very common affecting about 80% of patients with Cushing.”
BackgroundRecurrent gain-of-function USP8 mutations in Cushing's disease
Ma, Z.-Y., Song, Z.-J., Chen, J.-H., Wang, Y.-F., Li, S.-Q., Zhou, L.-F., Mao, Y., Li, Y.-M., Hu, R.-G., Zhang, Z.-Y., et al. (2015) · Cell Research · doi:10.1038/cr.2015.20 · Cited by 368
Stress and obesity: the role of the hypothalamic–pituitary–adrenal axis in metabolic disease
Bose, M., Oliván, B., & Laferrère, B. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832fa137 · Cited by 358
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study
Agustsson, T. T., Baldvinsdottir, T., Jonasson, J. G., Olafsdottir, E., Steinthorsdottir, V., Sigurdsson, G., Thorsson, A. V., Carroll, P. V., Korbonits, M., & Benediktsson, R. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0189 · Cited by 347
Cushing's syndrome: update on signs, symptoms and biochemical screening
Nieman, L. K. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0464 · Cited by 343
Self-citationSherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
“Overall, the consensus from these recommendations supports the use of the 1-mg DST as having the highest sensitivity for screening for ACS, Table 6.”
MethodInfluentialSelf-citationDiagnosis and Management of Pituitary Adenomas: A Review
Tritos, N. A., & Miller, K. K. (2023) · JAMA · doi:10.1001/jama.2023.5444 · Cited by 331
Adrenocortical zonation in humans under normal and pathological conditions
Nishimoto, K., Nakagawa, K., Li, D., Kosaka, T., Oya, M., Mikami, S., Shibata, H., Itoh, H., Mitani, F., Yamazaki, T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2010 · Cited by 310
Cawood, T. J., Hunt, P. J., O'Shea, D., Cole, D., & Soule, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0234 · Cited by 300
Approach to the patient with an adrenal incidentaloma
Nieman, L. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0457 · Cited by 290
Self-citationEpidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas
Ntali, G., & Wass, J. A. (2018) · Pituitary · doi:10.1007/s11102-018-0869-3 · Cited by 285
“• Screening for glucocorticoid excess (overnight dexamethasone suppression test, 24 h urinary free cortisol, midnight salivary cortisol) [91, 92] may be considered, regardless of clinical suspicion”
BackgroundNANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
Vinik, A. I., Woltering, E. A., Warner, R. R. P., Caplin, M., O'Dorisio, T. M., Wiseman, G. A., Coppola, D., & Go, V. L. W. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebaffd · Cited by 287
“In some cases, a serum midnight cortisol or dexamethasone-corticotropin releasing hormone test should be done.(103)”
BackgroundDiagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
“Second, the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3, 14, 23), and several comorbidities (i.”
BackgroundInfluentialCortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas
Debono, M., Bradburn, M., Bull, M., Harrison, B., Ross, R. J., & Newell-Price, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3007 · Cited by 269
Self-citationHair cortisol analysis: An update on methodological considerations and clinical applications
Greff, M. J. E., Levine, J. M., Abuzgaia, A. M., Elzagallaai, A. A., Rieder, M. J., & van Uum, S. H. M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.09.010 · Cited by 260
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Approach to the Patient with Possible Cushing’s Syndrome
Boscaro, M., & Arnaldi, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0612 · Cited by 251
“To enhance its sensitivity, the original postdexamethasone serum cortisol cutoff of 5 g/dl (138 nmol/liter) was reduced to 50 nmol/liter, and recently, this value was confirmed (9, 10).”
BackgroundMethodInfluentialRecurrent activating mutation in PRKACA in cortisol-producing adrenal tumors
Goh, G., Scholl, U. I., Healy, J. M., Choi, M., Prasad, M. L., Nelson-Williams, C., Kunstman, J. W., Korah, R., Suttorp, A.-C., Dietrich, D., et al. (2014) · Nature Genetics · doi:10.1038/ng.2956 · Cited by 251
“The diagnosis was based on elevated 24-hour urinary cortisol with suppressed ACTH level and/or pathological (i.e. non-suppressed) dexamethasone suppression test, and an adrenal tumor 28 .”
Bancos, I., Taylor, A. E., Chortis, V., Sitch, A. J., Jenkinson, C., Davidge-Pitts, C. J., Lang, K., Tsagarakis, S., Macech, M., Riester, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30218-7 · Cited by 250
ACOG Practice Bulletin No. 194: polycystic ovary syndrome
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002656 · Cited by 231
Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome
Cao, Y., He, M., Gao, Z., Peng, Y., Li, Y., Li, L., Zhou, W., Li, X., Zhong, X., Lei, Y., et al. (2014) · Science · doi:10.1126/science.1249480 · Cited by 232
Kanaji, N. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.197 · Cited by 227
Salivary cortisone is a potential biomarker for serum free cortisol
Perogamvros, I., Keevil, B. G., Ray, D. W., & Trainer, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1215 · Cited by 222
“Salivary cortisol has been used as a surrogate for free serum cortisol and has gained wide acceptance, especially in psychological and stress research (11), the diagnosis of Cushing’s syndrome (12), and the investigation of hypoadrenalism (13, 14), although the evidence on monitoring hydrocortisone replacement has bee…”
MethodKamenický, P., Droumaguet, C., Salenave, S., Blanchard, A., Jublanc, C., Gautier, J.-F., Brailly-Tabard, S., Leboulleux, S., Schlumberger, M., Baudin, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0536 · Cited by 221
Bertagna, X., Guignat, L., Groussin, L., & Bertherat, J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.001 · Cited by 222
Hair analysis provides a historical record of cortisol levels in Cushing's syndrome
Thomson, S., Koren, G., Fraser, L.-A., Rieder, M., Friedman, T. C., & Van Uum, S. H. M. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1220771 · Cited by 218
“The degree of cortisol over production is usually assessed by measuring twenty-four hour urinary free cortisol excretion ( Mengden et al., 1992 ), although serum cortisol levels after dexamethasone suppression and night-time serum and salivary cortisol levels are also used ( Nieman et al., 2008 ).”
MethodCushing's disease: pathobiology, diagnosis, and management
Lonser, R. R., Nieman, L., & Oldfield, E. H. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152119 · Cited by 215
“72 surgical treatment selective adenomectomy Successful adenomectomy eradicates the ACTH-secreting adenoma and immediately eliminates excess cortisol production while maintaining normal pituitary function (Fig.”
BackgroundSelf-citationClinical applications of cortisol measurements in hair
Wester, V. L., & van Rossum, E. F. C. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0313 · Cited by 210
Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome
Sato, Y., Maekawa, S., Ishii, R., Sanada, M., Morikawa, T., Shiraishi, Y., Yoshida, K., Nagata, Y., Sato-Otsubo, A., Yoshizato, T., et al. (2014) · Science · doi:10.1126/science.1252328 · Cited by 209
Cushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
“8 μg/dL (50 nmol/L) at the end of either test excludes Cushing’s syndrome (Table 2).(19) Variable absorption and metabolism of dexamethasone can affect the results of the DSTs.”
InfluentialSelf-citationTritos, N. A., Biller, B. M. K., & Swearingen, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.12 · Cited by 208
Self-citationIncidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208
“The diagnosis of CS was based on general diagnostic criteria, depending on availability of standardized biochemical tests and imaging techniques (1, 17).”
MethodAlexandraki, K. I., Kaltsas, G. A., Isidori, A. M., Storr, H. L., Afshar, F., Sabin, I., Akker, S. A., Chew, S. L., Drake, W. M., Monson, J. P., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0921 · Cited by 203
Approach to the Patient With Adrenal Incidentaloma
Bancos, I., & Prete, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab512 · Cited by 201
Deutschbein, T., Reimondo, G., Di Dalmazi, G., Bancos, I., Patrova, J., Vassiliadi, D. A., Nekić, A. B., Debono, M., Lardo, P., Ceccato, F., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00100-0 · Cited by 205
Self-citationTASK channel deletion in mice causes primary hyperaldosteronism
Davies, L. A., Hu, C., Guagliardo, N. A., Sen, N., Chen, X., Talley, E. M., Carey, R. M., Bayliss, D. A., & Barrett, P. Q. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712000105 · Cited by 198
Measurement of salivary cortisol in 2012 – laboratory techniques and clinical indications
Inder, W. J., Dimeski, G., & Russell, A. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04508.x · Cited by 195
Clinical and Organizational Factors in the Initial Evaluation of Patients With Lung Cancer
Ost, D. E., Jim Yeung, S.-C., Tanoue, L. T., & Gould, M. K. (2013) · Chest · doi:10.1378/chest.12-2352 · Cited by 195
The double challenge of resistant hypertension and chronic kidney disease
Rossignol, P., Massy, Z. A., Azizi, M., Bakris, G., Ritz, E., Covic, A., Goldsmith, D., Heine, G. H., Jager, K. J., Kanbay, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00418-3 · Cited by 194
Chiodini, I., Morelli, V., Salcuni, A. S., Eller-Vainicher, C., Torlontano, M., Coletti, F., Iorio, L., Cuttitta, A., Ambrosio, A., Vicentini, L., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2387 · Cited by 191
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Pregnancy and pituitary disorders
Karaca, Z., Tanriverdi, F., Unluhizarci, K., & Kelestimur, F. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0923 · Cited by 191
Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas
Castinetti, F., Nagai, M., Morange, I., Dufour, H., Caron, P., Chanson, P., Cortet-Rudelli, C., Kuhn, J.-M., Conte-Devolx, B., Regis, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2772 · Cited by 187
Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency
Raff, H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1166 · Cited by 186
Di Dalmazi, G., Vicennati, V., Rinaldi, E., Morselli-Labate, A. M., Giampalma, E., Mosconi, C., Pagotto, U., & Pasquali, R. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1039 · Cited by 184
European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
Pasquali, R., Casanueva, F., Haluzik, M., van Hulsteijn, L., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0893 · Cited by 188
Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients
Rubinstein, G., Osswald, A., Hoster, E., Losa, M., Elenkova, A., Zacharieva, S., Machado, M. C., Hanzu, F. A., Zopp, S., Ritzel, K., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz136 · Cited by 180
Expression and Mutations of KCNJ5 mRNA in Japanese Patients with Aldosterone-Producing Adenomas
Taguchi, R., Yamada, M., Nakajima, Y., Satoh, T., Hashimoto, K., Shibusawa, N., Ozawa, A., Okada, S., Rokutanda, N., Takata, D., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2885 · Cited by 178
“A diagnosis of Cushing’s syndrome was made in five cases [five females, aged 53.0 17.6 yr (mean SD)] according to guidelines published by The Endocrine Society (18).”
MethodInfluentialChan, S. M. H., Selemidis, S., Bozinovski, S., & Vlahos, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.013 · Cited by 177
“In addition to exogenous administration, endogenous biosynthesis and degradation of steroid hormones also appear to play a role in the development of MetS. Tobacco contains 11β-hydroxysteroid dehydrogenase type 2 inhibitor -glycyrrhizic acid which can inhibit the conversion of cortisol to inactive cortisone (Gilbert &…”
BackgroundCushing’s disease: the burden of illness
Pivonello, R., De Martino, M. C., De Leo, M., Simeoli, C., & Colao, A. (2017) · Endocrine · doi:10.1007/s12020-016-0984-8 · Cited by 171
Baudrand, R., Campino, C., Carvajal, C. A., Olivieri, O., Guidi, G., Faccini, G., Vöhringer, P. A., Cerda, J., Owen, G., Kalergis, A. M., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12225 · Cited by 170
Chiodini, I., Morelli, V., Masserini, B., Salcuni, A. S., Eller-Vainicher, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Carnevale, V., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0468 · Cited by 168
Bancos, I., Alahdab, F., Crowley, R. K., Chortis, V., Delivanis, D. A., Erickson, D., Natt, N., Terzolo, M., Arlt, W., Young, W. F., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0465 · Cited by 168
Pituitary adenomas: an overview.
Lake, M. G., Krook, L. S., & Cruz, S. V. (2013) · PubMed · Cited by 193
Gadelha, M., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 168
Wind, J. J., Lonser, R. R., Nieman, L. K., DeVroom, H. L., Chang, R., & Oldfield, E. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3943 · Cited by 165
“Lateralization in basal (pre-CRH) samples only 10 (2)”
BackgroundSelf-citationCushing Syndrome in Pediatrics
Stratakis, C. A. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.08.002 · Cited by 162
“8 mg/dL, further evaluation is necessary.(17) This test has a low percentage of false-normal suppression; however, the percentage of false positives is higher (approximately 15% to 20%).”
BackgroundMerits and pitfalls of mifepristone in Cushing's syndrome
Castinetti, F., Fassnacht, M., Johanssen, S., Terzolo, M., Bouchard, P., Chanson, P., Do Cao, C., Morange, I., Picó, A., Ouzounian, S., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0098 · Cited by 163
A review of rhythm and responsiveness of cortisol in individuals with autism spectrum disorders
Taylor, J. L., & Corbett, B. A. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.07.015 · Cited by 162
“It is important to note that hypercortisol and hypocortisol secretion are symptoms of two relatively rare endocrine disorders; namely, Cushing Syndrome (e.g., Cushing, 1932; Nieman et al., 2008) and Addison’s Disease (e.g., Husebye et al., 2013; Ten et al., 2001), respectively.”
BackgroundDelayed Remission after Transsphenoidal Surgery in Patients with Cushing’s Disease
Valassi, E., Biller, B. M. K., Swearingen, B., Pecori Giraldi, F., Losa, M., Mortini, P., Hayden, D., Cavagnini, F., & Klibanski, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1672 · Cited by 160
“Although patients were referred to tertiary centers based upon different local testing protocols, all had abnormal values on at least two of the following tests as described in recent consensus guidelines: 24-h urinary free cortisol (UFC), late-night salivary or serum cortisol, 1-mg overnight dexamethasone suppression…”
Self-citationde Laat, J. M., Dekkers, O. M., Pieterman, C. R. C., Kluijfhout, W. P., Hermus, A. R., Pereira, A. M., van der Horst-Schrivers, A. N., Drent, M. L., Bisschop, P. H., Havekes, B., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2015 · Cited by 160
“Classification of the different types of hypersecreting PIT (prolactinoma, somatotroph adenoma, corticotroph adenoma, gonadotroph adenoma and cose-creting PIT) was based on current recommendations and guidelines (3, 4, 14–16).”
Regulation of cortisol bioavailability—effects on hormone measurement and action
Perogamvros, I., Ray, D. W., & Trainer, P. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.134 · Cited by 158
Petersenn, S., Beckers, A. M., Ferone, D., van der Lely, A., Bollerslev, J., Boscaro, M., Brue, T. C., Bruzzi, P., Casanueva, F. F., Chanson, P., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0883 · Cited by 162
Normal and Premature Adrenarche
Rosenfield, R. L. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab009 · Cited by 187
Outcome of Surgical Treatment of 200 Children With Cushing's Disease
Lonser, R. R., Wind, J. J., Nieman, L. K., Weil, R. J., DeVroom, H. L., & Oldfield, E. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3604 · Cited by 160
Self-citation
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.